Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant

BACKGROUND: The phase III MONALEESA-3 trial included first- (1L) and second-line (2L) patients and demonstrated a significant overall survival (OS) benefit for ribociclib + fulvestrant in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative (HR+/HER2−) advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Neven, P., Fasching, P. A., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Martín, M., Nusch, A., Sonke, G. S., De la Cruz-Merino, L., Beck, J. T., Zarate, J. P., Wang, Y., Chakravartty, A., Wang, C., Slamon, D. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469877/
https://www.ncbi.nlm.nih.gov/pubmed/37653397
http://dx.doi.org/10.1186/s13058-023-01701-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469877/
https://www.ncbi.nlm.nih.gov/pubmed/37653397
http://dx.doi.org/10.1186/s13058-023-01701-9

Ejemplares similares